Not yet a member?
I recently heard a fascinating presentation by Dr. Paul Okunieff, a leader in radiation oncology. Dr. Okunieff recently relocated to my home state to become the director of the University of Florida Shands Cancer Center. He discussed his pioneering work on treating patients with just a few sites of metastatic cancer (a condition known [...]
24 CommentsIn this audio interview with Dr. Vivek Mehta, Radiation Oncologist and Director of the Center for Advanced Targeted Radiotherapy at Swedish Cancer Institute, Dr. Mehta explains current and emerging new radiation techniques, as well as the current state of radiation therapy to treat patients with “medically unresectable” early stage NSCLC, or patients who decline the option [...]
Podcast: Play in new window | Download
0 CommentsVivek Mehta, Radiation Oncologist, on radiation approaches for early stage and locally advanced NSCLC.
Transcript: V Mehta Interview I Transcript
Podcast: Play in new window | Download
0 Comments Some patients with small and early stage lung cancer are not able to undergo a surgical resection because of other medical conditions that might make an operation too risky. In this patient population, radiotherapy alone has often been the primary treatment.
Radiation is a very effective treatment modality for patients with any type of [...]
One emerging alternative to standard radiation therapy for medically inoperable patients with early stage NSCLC is stereotactic body radiation therapy (SBRT). This technique requires fixation and very precise treatment planning for a brief course of radiation that targets a more limited radiation field. One key issue with SBRT is that [...]
2 CommentsMany patients with early stage NSCLC but marginal or just plain poor pulmonary function tests and/or significant comorbidities pursue non-surgical therapy options rather than resection of the cancer. This primarily entails definitive radiation therapy (RT), stereotactic body radiation therapy (SBRT), or radiofrequency ablation (RFA) of these lung tumors. There is far more experience with [...]
6 CommentsWhile PCI is a recommended component of aggressive multimodality treatment for LD-SCLC, PCI does not at this time have any clear role in the treatment of NSCLC. To be potentially valuable, the risk of brain metastases needs to be high enough to justify to potential side effects, time, and expense [...]
5 Comments